If your real question is, “What is the cheapest GLP-1 option that still makes sense?” the answer is usually not “whatever has the lowest ad price.” In most cases, the best option is the cheapest transparent brand path you can get, because that gives you FDA-reviewed labeling, fixed dose strengths, and the strongest trial-backed evidence. Compounded GLP-1s and microdose programs can look cheaper or gentler at checkout, but they often ask you to accept more uncertainty in exchange for that lower sticker price. [1] [2] [5] [6] [8] [9]
That framing matters because these three buckets are not actually parallel. Brand is a regulatory category. Compounded is a pharmacy-made alternative that is not FDA-approved. Microdose is usually a program label or dosing strategy, not a formal FDA approval class. If you keep those lanes separate, the comparison gets much easier. For adjacent context, read our cheapest GLP-1 guide, telehealth comparison, insurance guide, and semaglutide guide.
What each bucket actually means
Brand GLP-1
Brand GLP-1s such as Wegovy and Zepbound are FDA-approved products with labeled titration schedules, labeled maintenance doses, and trial data tied to the exact product being sold. Wegovy starts at 0.25 mg weekly and escalates to a maintenance dose of 2.4 mg weekly, with 1.7 mg as an alternate maintenance dose. Zepbound starts at 2.5 mg weekly for 4 weeks, but that 2.5 mg dose is not approved as a maintenance dose; recommended maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg weekly. [5] [6]
That is what you are paying for with a brand product: the evidence package, the dose structure, and the manufacturing controls all line up.
Compounded GLP-1
Compounded GLP-1s are not FDA-approved. FDA says they should only be used when a patient’s medical needs cannot be met by an FDA-approved drug, or when the FDA-approved drug is not commercially available. [1] In other words, compounding can be appropriate in some cases, but it is not supposed to be treated like a routine generic substitute for brand semaglutide or tirzepatide.
The practical problem is that compounded products can differ in concentration, packaging, and dosing instructions. FDA has specifically warned that patients and clinicians have made dosing mistakes with compounded semaglutide and that some patients needed medical attention or hospitalization. [2]
Microdose programs
“Microdose GLP-1” is usually a program term, not a regulatory one. One current example is Noom’s Microdose GLP-1 program, which markets lower doses as an easier start with fewer side effects and plans starting at $79 for the first 4 weeks, then $199 per month on its 12-week subscription. The same page also says that if compounded medications are used, those compounded medications are not FDA-approved or reviewed for quality, safety, or efficacy. [7]
That is the key point: a microdose program is not automatically a third clean lane between brand and compounding. Sometimes it is a lower-dose, behavior-support wrapper around a compounded-medication path.
The fast comparison table
| Option | What you are actually buying | FDA status | Evidence strength | Current price examples I verified | Best fit | Main risk |
|---|---|---|---|---|---|---|
| Brand GLP-1 | Approved drug with labeled dosing and maintenance targets | FDA-approved | Strongest | Wegovy offers can run as low as $25 for eligible patients, with some self-pay options at $149 to $199 depending on product and dose; Zepbound self-pay starts at $299, then $399 or $449 depending on dose [8] [9] | Buyer who wants the clearest evidence and product consistency | Cost can still be high without coverage |
| Compounded GLP-1 | Pharmacy-made alternative that may copy or customize the active ingredient | Not FDA-approved | Weaker and less standardized | Price varies widely; offers are often cheaper upfront but less apples-to-apples | Buyer with a real patient-specific need the brand product cannot meet | More dosing, sourcing, and quality uncertainty [1] [2] |
| Microdose program | A lower-dose or customized program design, often bundled with coaching and telehealth support | Depends on what medication is actually used | Mixed | One current example starts at $79 for 4 weeks, then $199/month thereafter [7] | Buyer focused on a lower-friction start and willing to inspect the medication model carefully | ”Microdose” can hide the fact that the medication is compounded, off-label in structure, or supported by weaker evidence |
What users usually misunderstand
1. “Microdose” is not the same thing as an approved lower maintenance dose
Approved brands already have starter doses. Wegovy starts low and escalates. Zepbound starts at 2.5 mg weekly, but Lilly’s label explicitly says that 2.5 mg is a treatment-initiation dose, not a maintenance dose. [5] [6]
So when a program markets “microdose” as if it were a third official category, slow down. Sometimes it is just rebranding “lower than the studied maintenance dose” as a feature. That may still be reasonable for some people, but it is not the same evidence package as the approved brand pathways.
2. Compounded is not the same as generic
FDA’s March 3, 2026 warning announcement matters here. The agency said it sent warning letters to 30 telehealth companies for false or misleading compounded-GLP-1 claims. [3] That should make you skeptical of any seller implying that a compounded product is basically the same as Wegovy or Zepbound.
The safer rule is simple: if the seller cannot clearly say whether the medication is FDA-approved, compounded, or both depending on eligibility, the price comparison is already contaminated.
3. Cheapest sticker price does not mean cheapest clean option
Brand pricing changed materially after the worst shortage era. Wegovy’s current cost page includes self-pay and savings offers that are much lower than many readers still assume, and Lilly’s Zepbound page posts transparent self-pay numbers by dose. [8] [9]
That does not make brand products cheap for everyone. It does mean the old lazy take of “brand is always wildly more expensive, so compounding is the only budget path” is not good enough in 2026.
4. Shortage-era logic does not automatically still apply
FDA says the semaglutide injection shortage was resolved on February 21, 2025, and its stated enforcement-discretion windows tied to that shortage have already ended. [4] That does not mean every access problem vanished at every local pharmacy, but it does mean the broad shortage-era story is stale.
Which type of buyer each option fits best
Brand is usually best for the buyer who wants the cleanest evidence
If your question is, “Which path gives me the strongest confidence that the dose, device, and trial data all match?” brand wins. STEP 1 found mean weight loss of 14.9% at 68 weeks with semaglutide 2.4 mg, and SURMOUNT-1 found mean weight loss of 15.0%, 19.5%, and 20.9% at 72 weeks with tirzepatide 5 mg, 10 mg, and 15 mg. [10] [11]
Those are not generic “some GLP-1 at some dose” claims. They are product-specific results tied to approved maintenance-dose programs.
Compounded may fit the buyer with a real medical or access exception
This is the narrower lane. If a prescriber can explain the patient-specific reason an FDA-approved product does not meet your needs, compounding can still enter the conversation. [1] But if the entire sales pitch is just “cheaper than brand,” that is not the same thing as a medical rationale.
Microdose programs may fit the buyer who wants a slower on-ramp and understands the tradeoff
A microdose program can make sense if your highest priorities are a lower upfront price, more coaching, and a gentler start. But the tradeoff is that you need to inspect the medication source and the evidence standard much more carefully. Noom, for example, markets weight loss up to 17 pounds in 60 days from self-reported user data and also discloses that compounded medications, when used, are not FDA-approved. [7]
That is not automatically bad. It is just different from buying into an FDA-reviewed label plus phase 3 maintenance-dose evidence.
When the cheapest option is a bad idea
The cheapest option is usually a bad option when:
- the site never clearly says whether the medication is FDA-approved or compounded
- the price is only an intro month and the refill math is buried
- the program is built around a starter dose with no clear plan for what happens next
- the offer uses “same as Wegovy” or “same as Zepbound” language without saying the product is compounded
- the seller cannot explain who is prescribing, where the medication ships from, or what concentration you are injecting
The compounded-dosing risk is not theoretical. FDA has already described variable concentrations, multi-dose vials, and unit-conversion mistakes as part of the problem. [2]
Red flags before checkout
Screenshot this section.
- The company leads with the word “microdose” but buries what medication you are actually receiving.
- The product sounds like a generic version of Wegovy or Zepbound even though it is compounded.
- The monthly price excludes medication, refill fees, or later dose increases.
- The company cannot show you whether the drug comes in a pen, single-dose vial, or multi-dose vial.
- The seller cannot explain why a compounded option is appropriate for you specifically.
- The price looks unreal until you realize it only covers the first four weeks.
- The site makes strong weight-loss promises using testimonials or self-reported data without telling you that the medication model is different from the brand trials.
Bottom line
If you want the cleanest answer, brand is usually the best cheap option when you can still make the math work. It is often less expensive than people assume in 2026, and it gives you the strongest dosing and evidence alignment. [8] [9]
Compounded GLP-1s belong in the narrower lane where a prescriber can explain the patient-specific need. Microdose programs belong in the “read every line before you pay” lane, because they may blend lower-dose marketing, coaching, and compounded medication into one offer. [1] [7]
If you are comparing checkout pages, ask one blunt question before you enter your card: am I paying for an FDA-approved product with a labeled maintenance-dose path, or am I paying for a cheaper story that shifts more uncertainty onto me?
Last reviewed: April 14, 2026
